Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma

• Main Authors: Shang-Yi Huang (Author), Tsai-Yun Chen (Author), Ching-Yuan Kuo (Author), Yeu-Chin Chen (Author), Sheng-Fung Lin (Author), Ming-Chih Chang (Author), Xinzhu Lv (Author), Betty Yang (Author), Cheng-Shyong Chang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM...